Ethyl pyruvate protects against lethal systemic inflammation by preventing HMGB1 release

Annals of the New York Academy of Sciences

Volumn 987, Issue , 2003, Pages 319-321

  Ulloa, Luis ^a   Fink, Mitchell P ^b   Tracey, Kevin J ^a  

^a North Shore LIJ Research Institute ^*  (United States)

^b Department of Critical Care Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CYTOKINE; ENDOTOXIN; HIGH MOBILITY GROUP B1 PROTEIN; PYRUVIC ACID; TUMOR NECROSIS FACTOR;

ACUTE PHASE RESPONSE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISEPSIS; CHRONIC DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; DRUG POTENCY; ENDOTOXEMIA; IMMUNITY; MACROPHAGE; MORTALITY; MOUSE; NONHUMAN; ORGAN INJURY; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN INDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALIA;

EID: 0037565265     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2003.tb06075.x     Document Type: Conference Paper

References (7)

1. BUTT, W. 2001. Septic shock. Pediatr. Clin. North Am. 48: 601-625.
2. PERITI, P. 2000. Current treatment of sepsis and endotoxemia. Expert Opin. Pharmacother. 1: 1203-1217.
3. REINHART, K. & W. KARZAI. 2001. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit. Care Med. 29: S121-S125.
4. WANG, H., O. BLOOM, M. ZHANG, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251.
5. OMBRELLINO, M., H. WANG, M.S. AJEMIAN, et al. 1999. Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock. Lancet 354: 1446-1447.
6. HOTCHKISS, R.S. & I.E. KARL. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348(2): 138-150.
7. SIMS, C.A., S. WATTANASIRICHAIGOON, M.J. MENCONI, et al. 2001. Ringer's ethyl pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats. Crit. Care Med. 29: 1513-1518.